Scholar Rock Holding SRRK
NASDAQ SRRK
$55.11 -0.83 (-1.48%)
As of: Sep 4, 2026 · 12:51 PM EDT

Scholar Rock Holding (SRRK) Consolidated Net Income (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Consolidated Net Income of -$101.4 million for Q1 2026, down 35.42% year-over-year from -$157.1 million in Q1 2025, and down 11.21% quarter-over-quarter from -$91.2 million in Q4 2025.

Analysis

Scholar Rock Holding (SRRK) Consolidated Net Income (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.

  • In Q1 2026, Consolidated Net Income fell 35.42% year-over-year to -$101.4 million; the TTM figure through Mar 2026 stood at -$717.0 million (down 168.23% YoY), while the FY2025 annual figure was -$377.7 million, down 53.37% from the prior year.
  • Consolidated Net Income for Q1 2026 stood at -$101.4 million, down from -$91.2 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$9.2 million in Q1 2022, with the low at -$263.8 million in Q2 2025.
  • The 5-year median for Consolidated Net Income is -$56.8 million (2024), against an average of -$80.3 million.
  • The sharpest annual moves came in 2022 and 2023: Consolidated Net Income soared 93.69% in 2022, then plunged 383.1% in 2023.
  • Scholar Rock Holding's Consolidated Net Income stood at -$42.1 million in 2022, then slipped by 18.84% to -$50.0 million in 2023, then sank by 32.75% to -$66.4 million in 2024, then sank by 37.37% to -$91.2 million in 2025, then declined by 11.21% to -$101.4 million in 2026.
  • Business Quant data shows SRRK's Consolidated Net Income at -$101.4 million in Q1 2026, -$91.2 million in Q4 2025, and -$260.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Scholar Rock Holding 7.21 Bn 7.21 Bn - -109.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -109.33 Mn
Mar 31, 2026 -101.38 Mn
Dec 31, 2025 -90.90 Mn
Sep 30, 2025 -102.15 Mn
Jun 30, 2025 -109.90 Mn
Mar 31, 2025 -74.68 Mn
Dec 31, 2024 -66.44 Mn
Sep 30, 2024 -64.44 Mn
Jun 30, 2024 -58.49 Mn
Mar 31, 2024 -56.83 Mn
Dec 31, 2023 -48.03 Mn
Sep 30, 2023 -43.67 Mn
Jun 30, 2023 -39.08 Mn
Mar 31, 2023 -40.51 Mn
Dec 31, 2022 -40.43 Mn
Sep 30, 2022 -43.86 Mn
Jun 30, 2022 -43.15 Mn
Mar 31, 2022 -6.93 Mn
Dec 31, 2021 -35.36 Mn
Sep 30, 2021 -37.08 Mn